Infusion Reactions: Experience in Oncology Day Care Unit

Detalhes bibliográficos
Autor(a) principal: Ponte, Sandra
Data de Publicação: 2021
Outros Autores: Cabral, Carla Santos, Cavaco, Patrícia, Matos, Leonor Vasconcelos de, Fernandes, Leonor
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://onco.news/index.php/journal/article/view/19
Resumo: The administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition.   The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions.    Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher’s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC).    The review of the patient’s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial preinfusion assessment of antineoplastic treatments.   In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices. 
id RCAP_5896b8861f66a078a2d31f38695dceeb
oai_identifier_str oai:oai.onco.news:article/19
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Infusion Reactions: Experience in Oncology Day Care UnitReações Infusionais: Relatos da experiência de um Hospital de Dia de OncologiaReações infusionaisFármacos antineoplásicosInfusional reactionsAntineoplasic drugsThe administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition.   The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions.    Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher’s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC).    The review of the patient’s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial preinfusion assessment of antineoplastic treatments.   In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices. A administração de fármacos antineoplásicos pode gerar reações de hipersensibilidade imediatas em Hospital de Dia de Oncologia. A incidência e a gravidade são difíceis de prever e os sinais e sintomas variam, podendo ir de reações cutâneas eritematosas a reações anafiláticas graves, com risco letal. A prevenção é fundamental para reduzir a prevalência e a gravidade destes eventos e o reconhecimento precoce é um elemento chave na resolução do quadro.    Definimos como objetivos do presente estudo: revisão das reações infusionais na nossa instituição, particularmente, sua gravidade, incidência, fármacos envolvidos, reações subsequentes, tipo de pré e pós-medicação administradas. Definimos ainda uma sub-análise para identificação de preditores para reações subsequentes.   Estudo observacional, retrospetivo e unicêntrico, de análise das notificações de reações infusionais ao longo de três anos. Foram colhidos dados demográficos e relativos à situação de reacção infusional. A análise dos dados foi realizada por meio de estatística descritiva, teste t, teste exato de Fisher e regressão logística, usando o software StataIC 15.1 (StataCorp LLC).    A revisão da história patológica e alérgica do doente, a monitorização da adesão medicamentosa da pré-medicação, a reconciliação terapêutica e vigilância de sinais vitais são essenciais na avaliação inicial pré-infusional aos tratamentos antineoplásicos.    No nosso estudo, a prevalência de reações infusionais aos taxanos e platinas está alinhada com relatos anteriores da literatura. Revisões institucionais sobre eventos adversos são cruciais para melhorar as práticas atuais e desenvolver protocolos de atuação mais eficientes.AEOP – Associação de Enfermagem Oncológica Portuguesa2021-06-07info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://onco.news/index.php/journal/article/view/19Onco.news; No. 42 (2021): Onco.News Journal (january-june); 38-42Onco.News; N.º 42 (2021): Revista Onco.News (janeiro-junho); 38-422183-69141646-7868reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://onco.news/index.php/journal/article/view/19https://onco.news/index.php/journal/article/view/19/25Direitos de Autor (c) 2021 Sandra Ponte, Carla Santos Cabral, Patrícia Cavaco, Leonor Vasconcelos de Matos, Leonor Fernandesinfo:eu-repo/semantics/openAccessPonte, SandraCabral, Carla SantosCavaco, PatríciaMatos, Leonor Vasconcelos deFernandes, Leonor2024-03-16T07:55:09Zoai:oai.onco.news:article/19Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T04:01:18.835468Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Infusion Reactions: Experience in Oncology Day Care Unit
Reações Infusionais: Relatos da experiência de um Hospital de Dia de Oncologia
title Infusion Reactions: Experience in Oncology Day Care Unit
spellingShingle Infusion Reactions: Experience in Oncology Day Care Unit
Ponte, Sandra
Reações infusionais
Fármacos antineoplásicos
Infusional reactions
Antineoplasic drugs
title_short Infusion Reactions: Experience in Oncology Day Care Unit
title_full Infusion Reactions: Experience in Oncology Day Care Unit
title_fullStr Infusion Reactions: Experience in Oncology Day Care Unit
title_full_unstemmed Infusion Reactions: Experience in Oncology Day Care Unit
title_sort Infusion Reactions: Experience in Oncology Day Care Unit
author Ponte, Sandra
author_facet Ponte, Sandra
Cabral, Carla Santos
Cavaco, Patrícia
Matos, Leonor Vasconcelos de
Fernandes, Leonor
author_role author
author2 Cabral, Carla Santos
Cavaco, Patrícia
Matos, Leonor Vasconcelos de
Fernandes, Leonor
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Ponte, Sandra
Cabral, Carla Santos
Cavaco, Patrícia
Matos, Leonor Vasconcelos de
Fernandes, Leonor
dc.subject.por.fl_str_mv Reações infusionais
Fármacos antineoplásicos
Infusional reactions
Antineoplasic drugs
topic Reações infusionais
Fármacos antineoplásicos
Infusional reactions
Antineoplasic drugs
description The administration of antineoplastic drugs can generate immediately hypersensitivity reactions, in Oncology-Day Care Unit hospitals. The incidence and severity are difficult to predict and the signs and symptoms vary, ranging from erythematous skin reactions to severe anaphylactic reactions, with a lethal risk. Prevention is essential to reduce the prevalence and severity of these events and early recognition is a key element in resolving the condition.   The objectives of the present study were: reviewing of infusion reactions in our institution, particularly, their severity, incidence, drug, subsequent reactions, type of pre- and post-medication administered. We also defined a sub-analysis to identify predictors for subsequent reactions.    Observational, retrospective and single-center study, analyzing the reports of infusion reactions over 3 years. Demographic data and information regarding the infusion reaction situation were collected. Data analysis was performed using descriptive statistics, t test, Fisher’s exact test and logistic regression, using the software StataIC 15.1 (StataCorp LLC).    The review of the patient’s pathological and allergic history, the monitoring compliance to premedication, therapeutic reconciliation and surveillance of vital signs are essential in the initial preinfusion assessment of antineoplastic treatments.   In our study, the prevalence of infusion reactions to taxanes and platinum is in line with previous reports in the literature. Institutional reviews of adverse events are crucial to improve current practices and develop more efficient practices. 
publishDate 2021
dc.date.none.fl_str_mv 2021-06-07
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://onco.news/index.php/journal/article/view/19
url https://onco.news/index.php/journal/article/view/19
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://onco.news/index.php/journal/article/view/19
https://onco.news/index.php/journal/article/view/19/25
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv AEOP – Associação de Enfermagem Oncológica Portuguesa
publisher.none.fl_str_mv AEOP – Associação de Enfermagem Oncológica Portuguesa
dc.source.none.fl_str_mv Onco.news; No. 42 (2021): Onco.News Journal (january-june); 38-42
Onco.News; N.º 42 (2021): Revista Onco.News (janeiro-junho); 38-42
2183-6914
1646-7868
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799138187137777664